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Vermeire et al. show that the cytosolic
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infection and induces type I interferon
(IFN-I) production in primary CD4+ T cells.
Effective IFN-I induction requires proviral
integration and expression of the HIV
protein Vpr, while Vpu counteracts cGAS-
mediated innate immune activation.
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Several pattern-recognition receptors sense HIV-1
replication products and induce type I interferon
(IFN-I) production under specific experimental condi-
tions. However, it is thought that viral sensing and
IFN induction are virtually absent in the main target
cells of HIV-1 in vivo. Here, we show that activated
CD4+ T cells sense HIV-1 infection through the cyto-
solic DNA sensor cGAS and mount a bioactive IFN-I
response. Efficient induction of IFN-I by HIV-1 infec-
tion requires proviral integration and is regulated
by newly expressed viral accessory proteins: Vpr
potentiates, while Vpu suppresses cGAS-dependent
IFN-I induction. Furthermore, Vpr also amplifies
innate sensing of HIV-1 infection in Vpx-treated den-
dritic cells. Our results identify cGAS as mediator of
an IFN-I response to HIV-1 infection in CD4+ T cells
and demonstrate that this response is modulated
by the viral accessory proteins Vpr and Vpu. Thus,
viral innate immune evasion is incomplete in the
main target cells of HIV-1.
INTRODUCTION
Type I interferons (IFN-I) are key players in the innate immune
response against viral pathogens. They comprise a group
of heterogeneous cytokines, including different subtypes of
IFN-a and IFN-b. Production of IFN-I is induced through
recognition of specific viral products by various pattern-recog-
nition receptors. IFN-I proteins mediate their antiviral effects
by stimulating transcription of numerous immunomodula-
tory and antiviral interferon-stimulated genes (ISGs). In recent
years, different ISGs with profound activity against HIV-1,
such as the restriction factors APOBEC3G, TRIM5a, BST2/
tetherin, and SAMHD1 and the resistance factor MX2, haveCe
This is an open access article under the CC BY-Nbeen identified (Merindol and Berthoux, 2015). In HIV-1-in-
fected patients, serum levels of IFN-I are elevated throughout
the course of infection (Hardy et al., 2013). Although IFN-I re-
sponses initially limit viral spread, prolonged exposure to IFN-I
in the chronic phase of HIV-1/SIV (simian immunodeficiency
virus) infection is associated with desensitization and/or detri-
mental hyper-immune activation and thus contributes to dis-
ease progression (Sivro et al., 2014). This paradox was clearly
illustrated in SIVmac-infected rhesus macaques, where both
in vivo blockage of IFN-I receptors and prolonged treatment
with IFN-I accelerated disease progression (Sandler et al.,
2014).
Plasmacytoid dendritic cells (pDCs) are known to produce
high levels of IFN-I in response to HIV-1 upon recognition of
HIV-1 RNA by TLR7 (Lepelley et al., 2011). During acute infec-
tion, they are most likely the main source of IFN-I (Kader et al.,
2013). However, levels of circulating pDCs, as well as their ca-
pacity to produce IFN-I, decrease during progressive infection,
suggesting that other cell types also contribute to IFN-I produc-
tion, particularly during the chronic phase of HIV-1 infection
(Nascimbeni et al., 2009). The nature of these IFN-I-producing
cell populations remains, however, unclear.
Besides TLR7, other pattern-recognition receptors, such as
the DNA sensors cGAS and IFI16, also recognize HIV-1 replica-
tion products (Gao et al., 2013; Jakobsen et al., 2013). Several
studies have shown that they can be triggered by HIV-1 in certain
cell types and experimental conditions, through either pre- (Gao
et al., 2013; Monroe et al., 2014) or post-integration (Lahaye
et al., 2013) mechanisms. While IFI16 was shown to drive pro-
inflammatory responses to HIV-1 in abortively infected resting
CD4+ T cells (Monroe et al., 2014) and in macrophages (Jakob-
sen et al., 2013), cGAS activation by HIV-1 has thus far only
been detected in monocyte-derived macrophages (MDMs) and
dendritic cells after Vpx treatment or in THP-1 cell lines (Gao
et al., 2013; Lahaye et al., 2013). During natural HIV-1 infection,
IFN-I induction is thought to be largely absent in HIV-1 target
cells as a consequence of effective evasion mechanisms (Ra-
saiyaah et al., 2013; Yan et al., 2010). Which cell populationsll Reports 17, 413–424, October 4, 2016 ª 2016 The Author(s). 413
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. HIV Induces an IFN-I Response in Primary CD4+ T Cells
(A) Fold change in IFN-a and IFN-bmRNA levels in primary CD4+ T cells infected with HIV-1 NL4-3-GFP-I (black bars) at 2, 4, or 6 days after infection, relative to
non-infected (gray bars) cells at day 2 (n = 8).
(B) IFN-I activity in supernatant of cells described in (A). The dashed line corresponds to the detection limit of the assay.
(C) Fold change in IFIT1 mRNA levels in cells described in (A).
(D) Flow cytometric analysis of non-treated or non-infected cells and primary CD4+ T cells treated with recombinant (rec) IFN-a (1,000 IU/mL, IFNa1b) or infected
with HIV-1 NL4-3 after intracellular staining for MxA, 3 days after infection or treatment. (Left and Middle) Histograms showing expression of MxA in a repre-
sentative experiment. (Right) Geometric mean fluorescence intensity (MFI) of MxA expression (n = 3 or 4).
(legend continued on next page)
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and sensing pathways contribute to increased levels of IFN-I
during chronic HIV-1 infection is currently unclear.
Here, we show that HIV-1 infection can induce a bioactive
IFN-I response in activated CD4+ T cells, demonstrating that viral
immune evasion is incomplete. IFN-I induction was dependent
on proviral integration, indicating that productive infection is
required for viral sensing. We identified the cytosolic receptor
cGAS as an HIV-1 sensor that induces IFN-I in infected CD4+
T cells. Furthermore, we found that the HIV-1 Vpr protein poten-
tiates the IFN-I response, in both CD4+ T cells and dendritic cells.
Conversely, the HIV-1 Vpu protein suppresses cGAS-mediated
IFN-I induction, independently of its ability to counteract the re-
striction factor and innate sensor tetherin. Thus, cGAS-depen-
dent immune sensing of HIV-1 in productively infected activated
CD4+ T cells may contribute to the high levels of IFN-I and hyper-
immune activation during chronic infection.
RESULTS
HIV Induces an IFN-I Response in Activated Primary
CD4+ T Cells
In order to determine if HIV-1 replication induces IFN-I responses
in CD4+ T cells, PHA/IL-2 (interleukin-2) activated primary cells
were infected with HIV-1 NL4-3 and expression of IFN-I and
different ISGswas evaluated (Figure S1A). A significant induction
of IFN-a and IFN-b mRNA (Figure 1A) and bioactive IFN-I (Fig-
ure 1B) was observed in the HIV-1-infected cultures. CD4+
T cells purified by standard methods contained very few remain-
ing pDCs and additional depletion of pDCs prior to HIV-1 infec-
tion excluded them as the source of IFN-I (Figure S1B). While
present in all donors, the levels of HIV-1-induced IFN-I mRNA
varied in CD4+ T cells derived from different donors and corre-
lated with the percentage of HIV-1-infected cells over time (Fig-
ure S1C). Similarly, IFN-I induction correlated with the levels of
spreading infection when different inocula of HIV-1 were used
(Figure S1D). In addition to IFN-I, multiple ISGs were induced,
including IFIT1 (Figures 1C and S1D) and MxA (MX1) (Figures
1D and S1E) as well as IFIT3, IFI44, and OAS1 mRNA and cell-
surface BST2 protein (data not shown). The induction of MxA
was comparable to that obtained after treatment with recombi-
nant IFN-a (Figure 1D). Infection with two primary HIV-1 group
M strains and an HIV-2 isolate also clearly induced IFIT1 and
bioactive IFN-I in primary CD4+ T cells (Figure 1E), confirming
that this effect is not restricted to a particular viral strain.
To determine if the IFN-I response induced by HIV-1 in CD4+
T cells suppresses HIV-1 replication, neutralizing antibodies
against IFN-a and/or IFN-b were added to infected T cell cul-
tures. In combination, these antibodies markedly decreased
induction of the ISG IFIT1 by HIV-1 (Figure 2A). When added
separately, the IFN-a and -b antibodies each enhanced HIV-1
replication to a similar extent. Combining both antibodies had
a more potent effect on the fraction of HIV-1-infected cells and
also enhanced virus production (Figure 2B). Thus, both IFN-a(E) Infection levels and IFN-I response in primary CD4+ T cells infected with T-cell-
cells at different time points after infection, measured by intracellular Gag staining
levels 5 days after infection relative to non-infected cells. (Right) IFN-I activity m
Graphs show data and mean (±SEM). *p < 0.05; **p < 0.01; ***p < 0.001 (Wilcoxoand -b contribute to the antiviral effect of HIV-induced IFN-I in
CD4+ T cells.
HIV-1 Proviral Integration Is Required for IFN-I Induction
in Primary CD4+ T Cells
To determine which steps of the HIV-1 replication cycle are
required for IFN-I induction, CD4+ T cells were infected with
HIV-1 NL4-3 in the presence of reverse-transcriptase (nevira-
pine) or integrase (raltegravir) inhibitors and compared to cells
treated with a protease inhibitor (ritonavir). Inhibition of reverse
transcription prevented, and suppression of integration strongly
reduced, IFN-I and IFIT1 mRNA induction by HIV-1. In compar-
ison, strong IFN-I induction was observed when integration was
allowed (Figures 3A and S2A). The importance of viral integra-
tion was confirmed with an HIV-1 NL4-3 construct containing
a D116N mutation that inactivates integrase (Engelman et al.,
1995) (Figures 3B and S2B). Since the number of remaining
Gag-expressing cells was much lower during infection with
HIV-1 D116N compared to infection in the presence of raltegra-
vir (Figures S2A and S2B), remaining levels of integration might
account for the modest IFN-I induction by HIV-1 observed
in the presence of raltegravir (Figure 3A). Similar to the inte-
grase-deficient virus, a tat-defective virus did not significantly
induce IFN-I and IFIT1 mRNA during single-cycle infection of
CD4+ T cells (Figures 3C and S2C). Thus, Tat-dependent
expression of viral genes, rather than the integration process
itself, triggers IFN-I induction in HIV-1-infected primary CD4+
T cells.
IFN-I Induction by HIV-1 in CD4+ T Cells Is Mediated
through the cGAS Pathway
To identify host innate sensing pathways triggered by HIV-1 in
CD4+ T cells, we performed short hairpin RNA (shRNA)-medi-
ated knockdown studies. Knockdown of the DNA-sensing
cGAS receptor in primary CD4+ T cells (Figure 4A) resulted
in a marked decrease of IFIT1 mRNA induction upon HIV-1
infection. The results were confirmed using three independent
shRNAs that decreased cGAS expression without affecting
cell survival or HIV-1 infection levels (Figures 4B and S3A–
S3C). Possibly due to prolonged culture of the primary cells prior
to infection, in this experimental set-up HIV-1 infection levels
were low (Figure S3A) and IFN-I induction was only detectable
in four out of seven donors, even though all of them showed
ISG induction and therefore likely produced low levels of
IFN-I. In the four donors with a detectable increase in IFN-I,
knockdown of cGAS strongly reduced IFN-b induction upon
HIV-1 infection (Figure 4C). In comparison, IFN-b and IFIT1 in-
duction were not markedly affected by cGAS knockdown
when synthetic cGAMP, the downstream product of cGAS,
was used to trigger the IFN-I response (Figure S3D). In mono-
cyte-derived dendritic cells (MDDCs), polyglutamine-binding
protein 1 (PQBP1) was recently shown to be required for
cGAS-mediated sensing of HIV-1 DNA (Yoh et al., 2015).line grown HIV-1 and HIV-2 primary isolates (n = 6). (Left) Percentage of infected
(HIV-1) or by surface CD4 staining (HIV-2). (Middle) Fold change in IFIT1mRNA
easured in supernatant of cells described above.
n matched pairs test was used). See also Figure S1.
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Figure 2. IFN-I Induced by HIV-1 in Primary CD4+ T Cells Suppresses Viral Replication
Primary CD4+ T cells were infected with HIV-1 NL4-3-GFP-I in the presence or absence of neutralizing antibodies against IFN-a and IFN-b as indicated.
(A) Fold change in IFIT1 mRNA levels at different time points after infection relative to non-infected non-treated cells at day 2 (n = 7 or 8).
(B) (Top) Percentage of infected cells (GFP+) and reverse-transcriptase (RT) activity in supernatant at different time points (days post infection) in a representative
experiment. (Bottom) Percentage of infected cells or RT activity at 4 or 6 days post infection relative to infection in absence of antibodies (n = 6 or 7).
Graphs in (A) show data andmean ± SEM. Graphs in the bottom panels of (B) represent mean ± SEM. *p < 0.05; **p < 0.01. Wilcoxonmatched pairs test was used
in (A). Kruskal-Wallis ANOVA followed byDunn’smultiple comparisons post hoc test (treated compared to untreated control) was used in the bottom panels of (B).However, knockdown of PQBP1 in CD4+ T cells did not affect
the IFN-I induction by HIV-1 (Figure S3E).
To further evaluate involvement of the cGAS pathway in HIV-1-
mediated IFN-I induction, we co-cultured shRNA-transduced
primary CD4+ T cells with HIV-1-infected MT4 T cells (Figure 4D),
which allows more efficient virus infection via cell-to-cell trans-
mission (Sourisseau et al., 2007). Co-culture for 24 hr resulted
in high levels of HIV-1-infected CD4+ T cells and significant
IFN-b induction. Importantly, IFN-b induction was not detected
in HIV-1-infected MT4 cells cultured alone, or in co-cultures of
non-infected MT4 cells and primary CD4+ T cells, verifying that
HIV-1-infected CD4+ T cells are the source of IFN-I (Figure 4E).
Inhibition of infection of the primary cells, by addition of replica-
tion inhibitors upon co-culture, eliminated IFN-I induction (data
not shown). We subsequently performed knockdown of the
known cGAS pathway members MD21D1/cGAS, TMEM173/
STING, TBK1, and IRF3 in this experimental setting. Knockdown
of cGAS as well as the downstream signaling molecules STING,
TBK1, and IRF3 strongly decreased IFN-b induction (Figures 4F,
S3F, and S3G). In sum, HIV-1 triggers the cGAS pathway in
primary CD4+ T cells.
Vpr Potentiates IFN-I Induction by HIV-1
The involvement of cGAS, a DNA sensor, suggests that recogni-
tion of reverse-transcribed HIV-1 cDNA is driving the innate
immune response to HIV-1 in CD4+ T cells. However, our results
also indicated that IFN-I induction is dependent on expression of416 Cell Reports 17, 413–424, October 4, 2016the HIV-1 provirus. Similar to cGAS-mediated sensing of HIV-1 in
Vpx-treated (MDDCs), we reasoned that newly expressed viral
proteins might be required for IFN-I induction in CD4+ T cells.
In Vpx-treated MDDCs, HIV-1 DNA sensing is dependent on
the interaction of newly expressed HIV-1 capsid (CA) with Cyclo-
philin A (CypA), which has been suggested to ‘‘unmask’’ HIV-1
DNA for recognition by cGAS (Lahaye et al., 2013; Manel et al.,
2010). We used the same panel of HIV-1 CA mutated viruses,
complemented with a wild-type (WT) capsid protein during pro-
duction (Manel et al., 2010). However, viruses expressing cap-
sids that are able (WT, T54A/N57A, Q63A/Q67A) or not (G89V)
to interact with CypA induced similar levels of IFN-I (Figure S4A).
Thus, IFN-I induction in HIV-1-infected CD4+ T cells does not
require CypA interaction with newly expressed capsid proteins.
We subsequently evaluated the role of the HIV-1 accessory
protein Vpr. This protein was shown to counteract IFN-I re-
sponses (Harman et al., 2011; Laguette et al., 2014), but stimu-
lating effects on ISG induction have also been described (Zahoor
et al., 2015; Zahoor et al., 2014). We found that vpr-defective
HIV-1 NL4-3 constructs induced much lower levels of IFN-I
and IFIT1 than the wild-type virus, despite similar infection rates
(Figure 5A; Figure S4B), suggesting a potentiating effect of Vpr
on innate immune activation. In agreement with previous work
(Trotard et al., 2015), the absence of Vpr did not affect or even
enhanced the IFN-I response in STING-expressing TZM-bl cells
(Figure S4C). Infection of CD4+ T cells with vpr-defective viruses
complemented with WT Vpr during production also induced only
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Figure 3. Type I IFN Induction in Primary CD4+ T Cells Requires HIV-1 Integration
Fold change in IFN-b mRNA levels relative to non-infected cells in primary CD4+ T cells of different donors infected with: (A) HIV-1 NL4-3 in the presence of a
reverse transcription inhibitor (nevirapine, nevi), integration inhibitor (raltegravir, ralt), or protease inhibitor (ritonavir, rito) 48 hr after infection (n = 8); (B) HIV-1
NL4-3 wild-type (HIVWT) or D116N integrase mutant (HIV D116N) 24 hr after infection (n = 8); and (C) HIV-1 NL4-3-HSA-I wild-type (HIVWT) or tat-defective virus
(HIV TatStop) in the presence of ritonavir 48 hr after infection (n = 7). Graphs show data andmean ±SEM. ns, not significant; **p < 0.01; ***p < 0.001. Friedman test
followed by Dunn’s multiple comparisons post hoc test (infected compared to non-infected control) was used. See also Figure S2.low levels of IFN-I (Figures 5B and S4D). Thus, de-novo-synthe-
sized, and not virion-incorporated, Vpr is responsible for efficient
IFN-I induction, which helps to explain why the IFN-I response
occurs post-integration. Reduced IFN-I induction was also
observed with an otherwise isogenic HIV-1 construct containing
a single Q65R substitution in Vpr, which is known to disrupt bind-
ing of Vpr to DCAF1 (DeHart et al., 2007). By contrast, viruses
expressing the Vpr R77Q variant, associated with reduced pro-
apoptotic activity of Vpr (Lum et al., 2003), induced a potent
IFN-I response (Figures 5C and S4E). Knockdown of DCAF1
strongly decreased induction of IFIT1 and IFN-b upon HIV-1
infection (Figure 5D), but did not affect residual IFN-I induction
by a vpr-defective virus (Figure S4F). Thus, DCAF1 clearly plays
a role in the Vpr potentiating effect. A similar result was obtained
when cells were treated with an inhibitor of TAK1, a key regulator
of the nuclear factor kB (NF-kB) signaling pathway, prior to infec-
tion. TAK1was previously suggested to bind Vpr and be required
for Vpr-mediated activation of NF-kB (Liu et al., 2014). The TAK1
inhibitor did not affect cell survival (data not shown) or HIV-1
infection levels but highly decreased IFN-I induction by WT
HIV-1. By contrast, remaining induction by a vpr-defective virus
was not affected, suggesting a Vpr-dependent effect (Figure 5E).
Together, these results indicate that de novo synthesized Vpr
potentiates the IFN-I response in a DCAF1- and TAK1-depen-
dent fashion.
Given the potentiating effect of Vpr on IFN-I production in acti-
vated CD4+ T cells, we investigated if Vpr may play a similar role
in other immune cells. Myeloid dendritic cells are usually largely
resistant to productive HIV-1 infection due to restriction by
SAMHD1. However, the addition of viral-like particles (VLPs) car-
rying Vpx allows HIV-1 infection and promotes cGAS-dependent
IFN-I release (Lahaye et al., 2013). Since HIV-1-infected T cells
aremore potent inducers of IFN-I in MDDCs than cell-free virions
(Puigdome`nech et al., 2013), we measured bioactive IFN-I levels
in co-cultures of Vpx-treated MDDCs and MT4 cells infected
with vpr-deficient or WT HIV-1 NL4-3 (Figure 5F). MDDCs
became productively infected, and similar levels of Gag+ cells
were observed with WT or vpr-deficient viruses. AlthoughHIV-1 infection of MDDCs was generally associated with IFN-I
release, production of type I IFN was strongly reduced in the
absence of Vpr (Figure 5G). Thus, Vpr potentiates IFN-I produc-
tion in both activated CD4+ T cells and dendritic cells.
Vpu Suppresses IFN-I Induction by HIV-1 in CD4+ T Cells
Finally, we evaluated the role of HIV-1 Vpu in regulating the IFN-I
response in CD4+ T cells, as several studies have indicated an
ability of Vpu to counteract IFN-I induction (Doehle et al., 2012;
Gala˜o et al., 2012; Sauter et al., 2015). We indeed found that
vpu-deleted HIV-1 NL4-3 constructs induced a stronger IFN-I
response thanWT viruses in primary CD4+ T cells (Figure 6A; Fig-
ure S5A). Such a suppressive effect of Vpu was suggested to
depend on counteraction of the restriction factor and innate
sensor tetherin (Gala˜o et al., 2012). However, Vpu is also able
to counteract IFN-I induction independently of tetherin by down-
stream inhibition of NF-kB activation (Hotter et al., 2013; Sauter
et al., 2015). To assess whether Vpu’s ability to downregulate
tetherin plays a role in suppressing the HIV-1-induced IFN-I
response in CD4+ T cells, we infected cells with HIV-1 NL4-3 vi-
ruses containing vpu alleles from different primate lentiviruses
with varying abilities to antagonize tetherin (Sauter et al., 2009).
All these Vpus suppressed the IFN-I response irrespectively of
their anti-tetherin activity (Figure 6B; Figure S5B). Notably, an
HIV-1 NL4-3 construct containing a mutation in the b-TrCP bind-
ing motif of Vpu (S52A) that impairs both anti-tetherin and anti-
NF-kB activity (Pickering et al., 2014) lost the ability to suppress
the HIV-1-induced IFN-I response (Figure 6B; Figure S5B). We
subsequently investigated if cGAS is required for IFN-I induction
by vpu-deleted viruses. Upon knockdown of cGAS, vpu-deleted
and WT viruses induced similarly low levels of IFN-b (Figure 6C),
suggesting that Vpu dampens the cGAS-dependent IFN-I
response to HIV-1 in primary CD4+ T cells.
To evaluate the combined effects of Vpu and Vpr on IFN-I in-
duction during HIV-1 infection, CD4+ T cells were infected with
matched HIV-1 NL4-3 viruses carrying a deletion in vpr, vpu, or
both genes. As both proteins may affect IFN-I induction via the
NF-kB pathway, we also investigated the effect of the TAK1Cell Reports 17, 413–424, October 4, 2016 417
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Figure 4. cGAS and Downstream Signaling Molecules Are Required for IFN-I Induction by HIV-1 in Primary CD4+ T Cells
(A) Experimental set-up 1 to measure host protein involvement in IFN-I induction by HIV-1: primary CD4+ T cells are transduced with pLKO.1 shRNA-encoding
vectors and activatedwith PHA/IL-2 for 3 days, and efficiently transduced cells are selected with puromycin for 3 days. Cells are subsequently infectedwith HIV-1
NL4-3-GFP-I virus, and IFIT1/IFN-b mRNA levels are measured 48 hr after infection.
(B) Fold change in IFIT1mRNA levels in HIV-1-infected cells described in (A), relative to non-infected (non inf) cells transducedwith a non-targeting shRNA control
vector (CTRL). NTD, non-transduced cells. cGAS #1, #2, and #3 are different shRNA sequences targeting cGAS (n = 6).
(C) Fold change in IFN-b mRNA levels in experiments described in (B) with detectable IFN-b induction (n = 4).
(D) Experimental set-up 2: primary CD4+ T cells transduced with shRNA-encoding vectors as described in (A) are co-cultured with MT4 cells infected with HIV-1
NL4-3-GFP-I virus. IFN-b mRNA levels are measured 24 hr after the start of co-culture.
(legend continued on next page)
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inhibitor on IFN-I induction by these viruses. The vpr-vpu-defi-
cient virus induced an IFN-I response that was intermediate be-
tween the one triggered by viruses containing individual defects
in vpr and vpu (Figures 6D and S5C). Thus, both accessory pro-
teins can exert their effect on IFN-I induction independently from
each other. A similar observation was made upon treatment with
the TAK1 inhibitor: in contrast to the vpr-deleted virus, the
vpr-vpu-deficient virus was markedly affected by the inhibitor
(Figure 6E and S5D). This supports that Vpu suppresses IFN-I
induction through the NF-kB pathway and shows that this effect
is particularly important in the presence of the potentiating effect
of Vpr on this pathway.
DISCUSSION
In the present study, we demonstrate that activatedCD4+ T cells,
the main targets for HIV replication in vivo, sense HIV-1 replica-
tion products and secrete bioactive IFN-I following induction
through a post-integration mechanism involving the cGAS
signaling pathway. Furthermore, we show that this response is
subject to potentiation by Vpr and counteraction by Vpu. These
findings are important, since IFN-I released from CD4+ T cells
during the chronic phase of HIV-1 infection may contribute to
the detrimental hyper-immune activation that drives progression
to AIDS.
Triggering of an innate immune response during wild-type
HIV-1 infection of non-manipulated primary cells has thus far
only been observed in pDCs and abortively infected resting
CD4+ T cells (Doitsh et al., 2014; Lepelley et al., 2011). In our
experiments, residual CD14-expressing cells were well below
0.1% (data not shown) and pDCs were virtually eliminated in
the purified CD4+ T cell population, arguing against a signifi-
cant contribution of these myeloid cells to the IFN-I response
we measured. Except for two studies showing induction of
ISGs (Nasr et al., 2012) or IFN-I (Imbeault et al., 2009), IFN-I
production was not observed after HIV-1 infection of the
main target of HIV in vivo, activated CD4+ T cells (Doehle
et al., 2012; Yan et al., 2010). In the present study, production
of IFN-I was considerably enhanced by high HIV-1 infection
levels, e.g., during spreading replication, and might be missed
in low-level single-round infection studies. In addition, IFN-I
induction was absent in MT4 cells (Figure S3F) and other
T cell lines (data not shown). These are possible reasons
why IFN-I induction in HIV-infected T cells was missed in
studies mentioned above.
While the ability of cGAS to sense HIV-1 DNA was previously
described, its activation is thought to be evaded under normal
infection conditions (Lahaye et al., 2013; Rasaiyaah et al.,(E) (Left) Expression of GFP and CD3 in co-cultures of primary CD4+ T cells (CD3h
HIV NL4-3-GFP-I (CD3low cells), 24 hr after start of co-culture in a representative
(Right) Fold change in IFN-bmRNA levels in cultures of non-infected primary CD4+
(MT4 non inf), MT4 cells infected with HIV NL4-3-GFP-I (MT4 HIV-1), or co-cultures
cells.
(F) Fold change in IFN-b mRNA levels in co-cultures of non-infected or HIV-1-
encoding shRNA targeting the indicated genes, with the shRNA control vector
co-cultures of CTRL cells and non-infected (non inf) MT4 cells.
(B), (C), (E), and (F) show data (data point symbols refer to individual donors) andm
See also Figure S3.2013). An important implication of our findings is that cGAS is
not just a silent sensor, but plays an active role during HIV-1
infection and therefore possibly during pathogenesis. In agree-
ment with this, a recent study demonstrated specific activation
of cGAS by HIV-1 in conventional dendritic cells derived from
elite controllers, possibly due to higher levels of cGAS in
these cells (Martin-Gayo et al., 2015). In light of our findings, it
will be interesting to evaluate if cGAS expression levels in
CD4+ T cells may affect the levels of inflammation and disease
outcome.
Our results clearly show that cGAS-mediated sensing occurs
after viral integration and requires de novo expression of viral
RNA or proteins, since integrase- or tat-deficient viruses or treat-
ment with an integrase inhibitor strongly reduced IFN-I induction.
How can post-integration sensing by cGAS be explained? Two
possible scenarios can be envisioned. First, it is possible that
newly expressed RNA triggers the cGAS pathway. Protection
against RNA virus infection by cGAS expression has been
demonstrated (Schoggins et al., 2014), and similar to the DNA
sensor PQBP1, hypothetically an RNA co-receptor might exist.
A second and more likely explanation is that cGAS recognizes
cytosolic DNA. This may be mitochondrial DNA aberrantly
released in the cytoplasm as a consequence of mitochondrial
stress induced by newly expressed viral proteins, as reported
in herpes simplex virus (HSV) infection (West et al., 2015).
Notably, several studies have shown that Vpr induces mitochon-
drial damage (Huang et al., 2012; Jacotot et al., 2001), which
might explain its enhancing effect on IFN-I induction in primary
CD4+ T cells. Alternatively, cytoplasmic HIV pre-integration com-
plex cDNA could be the pathogen-associated molecular pattern
(PAMP) sensed and IFN-I production could be stimulated above
a critical threshold by a newly expressed viral protein, e.g.,
through additional NF-kB activation. These HIV DNA products
could originate from either simultaneous or previous abortive
infection events. Although further studies will be needed to
demonstrate a similar post-integration sensing mechanism dur-
ing HIV cell-to-cell transmission, it is know that this mode of
infection allows for the simultaneous transmission of many vi-
rions (Del Portillo et al., 2011; Sigal et al., 2011). Even though
most of these will fail to establish productive infection, their
reverse-transcription products could be targeted for cGAS
detection by a successfully integrated virus. HIV co-infection
has been primarily detected in splenic tissues of patients (Grat-
ton et al., 2000; Jung et al., 2002) where B and T lymphocytes,
but not pDCs, were found to be the IFN-a producing cells
(Nascimbeni et al., 2009). In such niches, cGAS-mediated
post-integration sensing could be a driving mechanism for
IFN-I production.igh cells) transduced with an shRNA control vector and MT4 cells infected with
experiment. P1, % CD3high cells; P1/P2, % GFP+ cells among CD3high cells.
T cells transduced with shRNA control vector (CD4+ T), non-infectedMT4 cells
of these cells (n = 3 or 4), relative to levels in co-cultures with non-infectedMT4
infected MT4 cells with primary CD4+ T cells transduced with either vectors
(CTRL) or non-transduced cells (NTD) (n = 4–6), relative to levels obtained in
ean. In (E), data indicate mean ± SEM. *p < 0.1; **p < 0.01 (Mann-Whitney test).
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Figure 5. Vpr Potentiates HIV-1-Mediated IFN-I Induction in Primary CD4+ T Cells and Dendritic Cells
(A–C) Innate immune response in HIV-1-infected primary CD4+ T cells relative to non-infected (non inf) cells.
(A) IFN-b mRNA levels 48–72 hr after infection with HIV-1 NL4-3-HSA-I wild-type (WT) or vpr- defective virus (dVpr) (n = 7).
(legend continued on next page)
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Figure 6. Vpu Suppresses cGAS-Mediated IFN-I Induction in Primary CD4+ T Cells
(A–D) IFN-I response in HIV-1-infected primary CD4+ T cells relative to non-infected (non inf) cells.
(A) IFN-b mRNA levels 48 hr after infection with VSV-G pseudotyped HIV-1 NL4-3-I-EGFP wild-type (WT) or vpu-deleted (dVpu) virus (n = 7).
(B) IFN-amRNA levels 48 hr after infection with VSV-G pseudotyped HIV-1 NL4-3-Vpu-IRES-Env viruses in which the original vpu allele was replaced by the vpu
allele of the indicated HIV-1 or SIV strain. Black bars show viruses with mutated NL4-3 vpu alleles, blue bars show viruses with vpu alleles that antagonize human
tetherin, red bars show viruses with vpu alleles that do not antagonize human tetherin (n = 4).
(C) IFN-b mRNA levels 48 hr after infection with VSV-G pseudotyped HIV-1 NL4-3-I-EGFP wild-type (WT) or vpu-deleted (dVpu) virus of cells transduced with
either shRNA-encoding lentiviruses targeting cGAS or a non-targeting control vector (CTRL) (n = 3 or 4).
(D) IFN-b mRNA levels 48 hr after infection with VSV-G pseudotyped HIV-1 NL4-3-I-EGFP wild-type (WT), vpu-deleted (dVpu), vpr-deleted (dVpr), or vpu- and
vpr-deleted (dVpu dVpr) viruses (n = 4).
(E) As described in (D), in the presence or absence of 50 nM of TAK1 inhibitor (5Z)-7-oxozeaenol (n = 6).
Graphs show data and mean ± SEM. *p < 0.05 (Wilcoxon matched pairs test). See also Figure S5.In Vpx-treated MDDCs, post-integration sensing of HIV-1
cDNA has been reported (Lahaye et al., 2013; Manel et al.,
2010). In contrast to MDDCs, in T cells the product that enables
the sensing of HIV DNA after integration is not the newly ex-
pressed HIV-1 capsid. Rather, we found that newly expressed
Vpr is required for full post-integration IFN-I induction since
vpr-deleted viruses induced lower levels of IFN-I in both CD4+(B) IFIT1mRNA levels 48 hr after infection with HIV-1 NL4-3-HSA-I wild-type (WT)
control vector (Ctrl) or WT Vpr (Vpr) during production. Infection was performed
(C) IFN-bmRNA levels 3 days after infection with HIV-1 NL4-3 viruses: wild-type (W
(D) IFIT1mRNA levels (left), IFN-bmRNA levels (middle), and percentage of HIV-1-
NL4-3-I-EGFP wild-type (WT) virus of cells transduced with either shRNA-encodi
transduced (NTD) (n = 2 or 4).
(E) IFIT1mRNA levels (left), IFN-bmRNA levels (middle), and percentage of HIV-1-
NL4-3-I-EGFP wild-type (WT) or vpr-defective (dVpr) viruses in the presence or a
(F) Experimental outline: MDDCs were pre-treated with Vpx VLPs to allow prod
vpr-deleted (dVpr) viruses and subsequently co-cultured with MDDCs. After 72
monitored by intracellular Gag staining.
(G) (Left) Percentage of HIV-1-infected MDDCs (Gag+) (n = 11). (Right) IFN-I acti
Graphs in (A)–(E) and (G) represent data (data point symbols refer to individual do
(Wilcoxon matched pairs test). See also Figure S4.T cells and Vpx-treated MDDCs. Virion complementation exper-
iments indicate that, at least in CD4+ T cells, virion-packaged
Vpr is insufficient to potentiate IFN-I induction. However, unlike
the integrase mutant, IFN-I induction by the vpr-deleted viruses
was not entirely absent in CD4+ T cells. Therefore, Vpr is most
likely an important, but not the sole, viral factor boosting
post-integration IFN-I induction. Our evaluation of vpr-mutatedor vpr- defective (dVpr) viruses, not complemented (-) or complemented with a
in the presence of ritonavir (n = 5).
T), vpr- deleted (dVpr), and viruses with Q65R or R77Qmutation in Vpr (n = 4).
infected cells (GFP+) (right) 48 hr after infection with VSV-G pseudotyped HIV-1
ng lentiviruses targeting DCAF1 or a non-targeting control vector (CTRL) or not
infected cells (GFP+) (right) 48 hr after infection with VSV-G pseudotyped HIV-1
bsence of 50 nM of TAK1 inhibitor (5Z)-7-oxozeaenol (n = 6).
uctive infection. MT4 cells were infected with HIV-1 NL4-3 wild-type (WT) or
hr, supernatant was harvested for quantification of IFN-I and infection was
vity in supernatant of co-cultures (n = 11).
nors) and mean. In (A)–(C), data indicate mean ± SEM. *p < 0.05; ***p < 0.001
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viruses and knockdown studies indicates that the interaction of
Vpr with DCAF1 is required for this effect. Vpr hijacks DCAF1
to recruit the DDB1-Cul4 E3 ubiquitin ligase complex. This com-
plex is involved in different Vpr functions (Casey et al., 2010).
However, activation of the DNA damage response by Vpr is
particularly interesting in this regard because of the large overlap
and interplay between cellular DNA damage response and acti-
vation of NF-kB or IRFs (Chatzinikolaou et al., 2014). We show
that IFN-I induction by wild-type HIV-1 but not a vpr-deleted de-
rivative is sensitive to inhibition of TAK1, which is consistent with
an activating effect of Vpr on NF-kB. As such, it is tempting to
speculate that stimulation of IFN-I production by Vpr may be
a by-product of a Vpr-host interaction with yet-to-be defined
beneficial effects during viral replication, e.g., an indirect effect
of the DNA damage response or a direct consequence of
NF-kB activation (Liu et al., 2014; Roesch et al., 2015; Roux
et al., 2000) to enhance proviral expression.
We also observe a potentiating effect of Vpr on IFN-I induction
by HIV-1 infection of Vpx-treated MDDCs as was recently
described for MDMs and non-Vpx-treated MDDCs (Zahoor
et al., 2014, 2015). In contrast, others showed a suppressive
role of Vpr in IFN-I production, either in non-Vpx-treated MDDCs
(Harman et al., 2011), in MDMs (Mashiba et al., 2014), or in cell
lines, such as HEK293 or HeLa (Doehle et al., 2009; Laguette
et al., 2014; Okumura et al., 2008; Trotard et al., 2015). Consis-
tent with these latter reports, we observed a suppressing effect
of Vpr on IFN-a induction in HeLa-derived STING-expressing
TZM-bl cells. These findings strongly suggest that the outcome
of the Vpr effect is cell-type dependent and questions the rele-
vance of cell lines as a model for sensing in activated T cells.
While the sensing pathway activated by the (vpr-deleted) HIV-1
in these studies is unknown, at least in TZM-bl cells activation
seems to occur prior to viral integration (Trotard et al.,
2015) and may therefore result from stimuli different from the
cGAS-mediated post-integration sensing in CD4+ T cells and
Vpx-treatedMDDCs (Lahaye et al., 2013). Furthermore, pre-inte-
gration sensing implies that the suppressing effect is mediated
by virion-packaged Vpr, while we show the newly expressed
Vpr to be responsible for potentiation of post-integration
sensing.
In line with previous reports (Doehle et al., 2012; Gala˜o et al.,
2012; Sauter et al., 2015), we found that Vpu efficiently sup-
presses IFN-I induction inHIV-1-infectedCD4+T cells. Our results
provide insight into the specific sensing pathway targeted by Vpu
and provide a rationale as to why a late HIV-1 protein is employed
by the virus to counteract IFN-I induction. Indeed, since Vpu is
only present in the infected cell after viral integration, it is likely
to have evolved as a counteracting factor of a post-integration
IFN-I trigger. Here, we show that sensing of vpu-deleted viruses
is cGAS dependent, indicating partial suppression of cGAS
sensing by Vpu rather than suppression of an alternative
independent IFN-I inducing pathway. Although it is possible that
enhanced tetherin-mediated NF-kB activation contributes to
higher IFN-I induction by vpu-deleted viruses (Gala˜o et al.,
2012), the cGAS dependency indicates that tetherin signaling on
its own is likely insufficient to trigger IFN-I production in CD4+
T cells. Furthermore, we show that HIV-1 and SIV isolates known
to employ Nef to counteract tetherin use Vpu to suppress HIV-1-422 Cell Reports 17, 413–424, October 4, 2016mediated IFN-I induction, again pointing to a tetherin-indepen-
dent function. We and others have demonstrated that Vpu sup-
pressesNF-kBactivation in response to various stimuli, a process
that is partially mediated by sequestration of b-TrCP by Vpu and
stabilization of IkBa (Besnard-Guerin et al., 2004; Bour et al.,
2001; Manganaro et al., 2015; Pickering et al., 2014; Sauter
et al., 2015). Our results with vpr-, vpu-, and vpr-vpu-deficient
viruses suggest that Vpu may counteract NF-kB activation by
Vpr and suppress a Vpr-independent trigger of NF-kB activation.
ActivationofSTING is indeedknown to induceactivationofNF-kB
on its own (Kato et al., 2013), and silencing of NF-kB p65 was
shown to decrease IFN-b production in response to dsDNA
(Abe andBarber, 2014). Therefore, Vpumay dampen IFN-I induc-
tion in primary CD4+ T cells by interfering with NF-kB activation,
the latter in part due to Vpr-enhanced cGAS-mediated sensing.
Our work provides insight in the virus-host interplay that regu-
lates HIV-1 sensing in its main target cells. Our identification
of HIV-1-infected CD4+ T cells as potential contributors to
IFN-I production and hence harmful chronic inflammation might
provide the basis for novel therapeutic strategies.
EXPERIMENTAL PROCEDURES
Viral constructs, the experimental outline, and applied methods are indicated
in the figure legends and explained in detail in the Supplemental Experimental
Procedures.
Quantification of IFN-I Responses
IFN-a, IFN-b, and IFIT1 mRNA levels were measured by qPCR using specific
primers as listed in the Supplemental Experimental Procedures. IFN-I biolog-
ical activity in the supernatant was measured using HL-116 luciferase reporter
cells. MxA protein levels were quantified by intracellular staining and flow
cytometry.
HIV Proviral Constructs and Infection
HIV-1NL4-3derivedconstructs are listed in theSupplemental ExperimentalPro-
cedures. Viruses were produced in HEK293T cells, complemented, if indicated,
by co-transfection with Gag- or Vpr-expressing plasmids. HIV-1 and HIV-2 iso-
lates were propagated in peripheral blood mononuclear cells (PBMCs) and
Jurkat CD4 CCR5 cells. Primary CD4+ T cells, obtained from blood of healthy
donors, underwent extra pDC depletion andwere infected with HIV by spinocu-
lationusing6–3,000mUreverse transcriptase of virusper250,000cells. Anti-ret-
rovirals, IFN-I neutralizingantibodies, and (5Z)-7-oxozeaenolwereaddedprior to
or immediately after spinoculation, respectively, and maintained during culture.
Monocytes were isolated from PBMCs and differentiated in the presence of
IL-4 andgranulocyte-macrophage colony-stimulating factor (GM-CSF).MDDCs
were treated with VLPs carrying Vpx and infected with HIV-1 through co-culture
with MT4 cells. The HIV-1 group M D2 (VI203) (Louwagie et al., 1993) and HIV-2
CI85 (Arien et al., 2005) strains were previously isolated from patients attending
the AIDS clinic at the Institute of Tropical Medicine in Antwerp, Belgium with the
approval of the ethical committee after written informed consent.
Knockdown of Host Genes and Co-culture with HIV-1-Infected Cells
The origin and properties of pLKO.1-puro shRNA-encoding lentiviral construct
are listed in the Supplemental Experimental Procedures. Lentiviruses were
produced in HEK293T cells using Mission Lentiviral Packaging Mix. Primary
CD4+ T cells were transduced using polybrene, stimulated with PHA/IL-2,
selected with puromycin, and infected with HIV-1 as described above or alter-
natively co-cultured with HIV-1-infected MT4 cells.
Statistical Analysis
Statistical tests were performed with GraphPad Prism 5.0 as indicated in the
figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.09.023.
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Figure S1 
 
 
 
Figure S1, related to Figure 1. 
Characterization of IFN-I response during HIV infection primary CD4+ T cells.  
(A) Experimental scheme to measure type 1 IFN (IFN-I) response: PHA/IL-2 activated, pDC depleted primary 
CD4+ T cells are infected with HIV. The IFN-I response is quantified by isolation of mRNA from the cells to 
measure IFN-α, IFN-β and IFN-stimulated gene (ISGs) expression by qPCR, by intracellular staining of the cells 
for MxA protein and by measuring IFN-I activity in the supernatant of the cells with the HL-116 reporter cell 
assay.  
(B) (Left) Dot-plots of flow cytometric data showing expression of pDC markers (CD123-FITC versus CD303-
APC) in PBMCs and purified CD4+ T cell populations with or without additional pDC depletion, immediately 
after isolation of cells in a representative experiment. Red dots represent cells gated on viable (propidium iodide-
negative) cells, blue represents cells with additional gating on CD304+CD123+ cells. Numbers indicate the 
percentage of CD304+CD123+CD303+ cells among viable cells. Graph shows average number of 
CD304+CD123+CD303+ cells per 250,000 cells detected as described above (n=6). Purified CD4+ T cells 
populations typically contained around 20 pDC’s per culture of 250,000 cells, while CD4+ T cells with additional 
pDC depletion contained ≤ 1 pDC per culture.  
(Middle) Fold change in IFN-β mRNA levels relative to non-infected cells and (left) IFN-I activity for purified 
CD4+ T cells with or without additional pDC depletion at peak levels of HIV NL4-3-GFP-I or HIV NL4-3-HSA-
I infection (4 or 6 days after infection) (n=6). 
(C) (Left) Fold change in IFN-β mRNA levels relative to non-infected cells, 4 days after HIV NL4-3-GFP-I or 
HIV NL4-3-HSA-I infection of primary CD4+ T cells derived from 14 different donors; (right) percentage of 
HIV infected cells (left y-axis) and fold change in IFN-β mRNA levels relative to non-infected cells (right y-
axis) at different time points after infection in cells of two of these donors.  
(D) Infection levels and IFN-I response in primary CD4+ T cells infected with the indicated amounts of HIV 
NL4-3 virus (mU RT activity) (n=3). (Left) Percentage of infected cells at different time points after infection, 
measured by intracellular p24 staining; (middle) IFN-I activity in supernatant of cells; (right) fold change in 
IFIT1 mRNA levels at different time points after infection, relative to non-infected cells at day 3.  
(E) Histograms showing expression of MxA in HIV NL4-3 infected or non-infected cells primary CD4+ T cells 
after intracellular staining with a rabbit polyclonal anti-MxA antibody or rabbit control serum, 3 days after 
infection. Ratio of mean fluorescence intensity of MxA stained over control stained infected cells: 3. 
Graphs in (B) and (D) show data and mean ± SEM. *p<0.05 (Wilcoxon matched pairs test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2 
 
 
 
 
 
 
 
 
Figure S2, related to Figure 3. 
Requirement of HIV-1 integration and Tat-mediated viral gene expression for IFN-I induction in primary 
CD4+ T cells.  
(Left) Fold change in IFN-α and IFIT1 mRNA in infected relative to non-infected (non inf) cells from different 
donors; (right) dot-plots of flow cytometric data showing side scatter (SSC) versus p24-PE (A, B) or HSA-APC 
(C) fluorescent intensity levels measured at the same time point in primary CD4+ T cells infected with:  
(A) HIV NL4-3 in the presence of a reverse transcription inhibitor (nevirapine, nevi), integration inhibitor 
(raltegravir, ralt) or protease inhibitor (ritonavir, rito) 48 h after infection (n=8). 
(B) HIV NL4-3 wild-type (HIV WT) or D116N integrase mutant (HIV D116N) 24 h after infection (n=8).  
(C) HIV NL4-3-HSA-I wild-type (HIV WT) or tat-defective virus (HIV TatStop) in the presence of ritonavir 48 
h after infection (n=7). 
Graphs show data and mean ± SEM.” ns” not significant, **p<0.01; ***p<0.001 (Friedman test followed by 
Dunn's multiple comparisons post hoc test, infected compared to non-infected control). 
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Figure S3, related to Figure 4. 
cGAS is required for IFN-I induction by HIV-1 in primary CD4+ T cells.  
(A) Percentage of GFP+ (HIV-1 infected) cells in cultures described in Figure 4B (n=6). cGAS #1-3 represents 
use of different shRNA sequences targeting cGAS; CTRL: cells transduced with a non-targeting shRNA control 
vector; NTD: non-transduced cells. 
(B) Percentage of propidium iodide-negative cells as indicated by FACS analysis of transduced cells described in 
Figure 4B, immediately prior to HIV-1 infection (n=6).  
(C) (Left) Percentage of remaining cGAS mRNA levels in cells described in Figure 4B, relative to levels in cells 
transduced with a non-targeting shRNA control vector (CTRL) (100%) immediately prior to HIV-1 infection 
(n=6). (Right) cGAS protein levels (50 and 60 kDa isoforms) and β-actin loading control in lysates of primary 
CD4+ T cells after transduction with indicated shRNA-encoding lentiviral vectors and puromycin selection. 
(D) Fold change in IFN-β (left) and IFIT1 (right) mRNA in cells transduced with indicated shRNA-encoding 
lentiviral vectors and stimulation with synthetic cGAMP (10 μg/mL) for 24 h, relative to non-treated (non tr) 
cells. cGAS #1-3 represents different shRNA sequences used to target cGAS; CTRL: cells transduced with a 
non-targeting shRNA control vector (n=2). 
(E) (Left) Fold change in IFIT1 mRNA in cells transduced with indicated shRNA-encoding lentiviral vectors 
and infected with VSV-G pseudotyped HIV NL4-3-I-EGFP for 48 h, relative to non-infected (non inf) cells. 
cGAS #3 and PQBP1 #1-2 represents different shRNA sequences used to target cGAS or PQBP1 respectively; 
CTRL: cells transduced with a non-targeting shRNA control vector. (Right) Percentage of remaining mRNA 
expression of the indicated genes in non-infected primary CD4+ T cells transduced with shRNA encoding 
vectors targeting PQBP1, relative to levels in cells transduced with a non-targeting shRNA control vector 
(100%) (n=3). 
(F) Percentage of remaining mRNA of the indicated genes in primary CD4+ T cells transduced with shRNA 
encoding pLKO.1 vectors targeting the indicated genes, relative to levels in cells transduced with a non-targeting 
shRNA control vector (100%) immediately prior to co-culture (n=2-4).  
(G) (Left) Percentage of remaining cGAS mRNA in primary CD4+ T cells transduced with additional shRNA 
encoding pLKO.1 vectors targeting cGAS, relative to levels in cells transduced with a non-targeting shRNA 
control vector (100%) immediately prior to co-culture (n=2). (Right) Fold change in IFN-β mRNA levels in co-
cultures of non-infected (non inf) or HIV NL4-3-GFP-I infected MT4 cells with primary CD4+ T cells 
transduced with shRNA-encoding vectors targeting cGAS or the shRNA control vector (CTRL), relative to 
levels obtained in co-cultures of CTRL cells and HIV-1 infected MT4 cells (n=2). 
Bar graphs in A-C and E, F, G (left), H represent mean ± SEM. Graphs in D, E (left), G (right) show data (data 
point symbols refer to individual donors) and mean; * p<0.05 (Wilcoxon signed-rank test). 
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Figure S4, related to Figure 5. 
Effect of HIV-1 Capsid-CypA interaction and Vpr on HIV-1 induced IFN-I response in primary CD4+ T 
cells.  
Infection levels and IFN-I response in primary CD4+ T cells, relative to non-infected (non inf) cells.  
(A) Infection with VSV-G pseudotyped HIV-1 LAI dEnv dNef viruses (WT) or with viruses with additional 
mutations in capsid (G89V, T54A/N57A, Q63A/Q67A), 48 h after infection (n=2). All viruses were 
complemented with WT capsid during production. (Left to right) Fold change in IFN-α, IFN-β or IFIT1 mRNA 
levels; percentage of infected cells (GFP+).  
(B) Infection with HIV NL4-3-HSA-I wild-type (WT) or vpr-defective virus (dVpr), 48-72 h after infection 
(n=7). (Left and middle) fold change in IFN-α and IFIT1 mRNA levels; (right) percentage of infected (HSA+) 
cells.  
(C) Infection of STING expressing TZM-bl cells with increasing concentrations of HIV NL4-3-HSA-I wild-type 
(WT) or vpr-defective virus (dVpr) (1100 to 4400 mU/mL RT activity), 48 h after infection (n=2). (Left and 
middle) fold change in IFN-α and IFIT1 mRNA levels relative to non-infected (non inf) cells; (right) percentage 
of infected (HSA+) cells. 
(D) Infection with HIV NL4-3-HSA-I vpr-defective (dVpr) or wild-type (WT) virus, not complemented (-), 
complemented with a control vector (Ctrl) or with WT Vpr (Vpr) during production. Infection was done in the 
presence of ritonavir (n=5). (Left) Fold change in IFN-β mRNA levels 48 h after infection; (right) percentage of 
infected (HSA+) cells (n=2). 
(E) Infection with HIV NL4-3 viruses: wild-type (WT), vpr-deleted (dVpr), viruses with Q65R or R77Q 
mutation in Vpr, 72 h after infection (n=4). (Left and middle) Fold change in IFN-α and IFIT1 mRNA; (right) 
percentage of infected (p24+) cells.  
(F) (left) IFIT1 mRNA levels, (middle) IFN-β mRNA levels and (right) percentage of HIV-1 infected cells 
(GFP+) 48 h after infection with VSV-G pseudotyped HIV NL4-3-I-EGFP wild-type (WT) or vpr-deleted 
(dVpr) virus of cells either not transduced (NTD) or transduced with either a non-targeting control vector 
(CTRL) or shRNA-encoding lentiviruses targeting DCAF1(n=1). Numbers indicated fold change in IFIT1 or 
IFN-β mRNA levels in “CTRL” versus “DCAF1” samples. 
Graphs in A, B, D-F show data and mean ± SEM. Graphs in C represent mean ± SEM *p<0.05 (Wilcoxon 
matched pairs test). 
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Figure S5, related to Figure 6.  
Effect of Vpu on HIV-1 induced IFN-I response in primary CD4+ T cells.  
Infection levels and IFN-I response in primary CD4+ T cells, relative to non-infected (non inf) cells.  
(A) Infection with VSV-G pseudotyped HIV NL4-3-I-EGFP vpu-deleted (dVpu) or wild-type (WT) virus, 48 h 
after infection (n=7). (Left and middle) fold change in IFN-α and IFIT1 mRNA levels; (right) percentage of 
infected (GFP+) cells.  
(B) Infection with VSV-G pseudotyped HIV-NL4-3-Vpu-IRES-Env viruses in which the original vpu allele was 
replaced by the vpu allele of the indicated HIV-1 or SIV strain. Black bars show viruses with mutated NL4-3 vpu 
alleles, blue bars show viruses with vpu alleles that antagonize human tetherin, red bars show viruses with vpu 
alleles that do antagonize human tetherin, 48 h after infection (n=4). (Left and middle) fold change in IFIT1 and 
IFN-β mRNA levels; (right) percentage of infected (p24+) cells.  
(C) Infection with VSV-G pseudotyped HIV NL4-3-I-EGFP wild-type (WT), vpu-deleted (dVpu), vpr-deleted 
(dVpr) or vpu- and vpr-deleted (dVpu dVpr) viruses, 48 h after infection (n=4). (Left and middle) Fold change in 
IFN-α and IFIT1 mRNA levels; (right) percentage of infected (GFP+) cells.  
(D) Infection with VSV-G pseudotyped HIV NL4-3-I-EGFP wild-type (WT), vpu-deleted (dVpu), vpr-deleted 
(dVpr) or vpu- and vpr-deleted (dVpu dVpr) viruses, 48 h after infection  in presence or absence of 50 nM of 
TAK1 inhibitor (5Z)-7-oxozeaenol (n=6). (Left and middle) Fold change in IFN-α and IFIT1 mRNA levels; 
(right) percentage of infected (GFP+) cells. 
Graphs show data and mean ± SEM. *p<0.05 (Wilcoxon matched pairs test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Experimental Procedures. 
 
Isolation and culture of cells 
Primary CD4+ T cells were isolated from buffy coats of healthy donors (Red Cross, Ghent, Belgium), donated 
after informed consent, approved by Ghent University ethical committee. Peripheral blood mononuclear cells 
(PBMCs) were obtained on Lymphoprep (Axis-Shield PoC, Oslo, Norway) and used for CD4+ T cell isolation 
by negative selection with a commercial kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
manufacturer’s instructions. Depletion of pDCs was done on PBMCs prior to isolation of CD4+ T cells, by 
negative selection after staining with CD304-PE antibody (clone AD5-17F6, Miltenyi Biotec) in the presence of 
human FcR blocking reagent (Miltenyi Biotec) and subsequent staining with anti-PE paramagnetic microbeads 
(Miltenyi Biotec). Purity of the CD4+ T cell population was measured by flow cytometry (MACSquant® 
Analyzer using MACSQuantify v2.4 software, Miltenyi Biotec), showing a fraction of at least 95 % CD4+CD3+ 
double positive cells and less than 0.0004 % CD123+CD304+CD303+ cells (measured on 1.5 x106 cells, 
corresponds to ≤1 pDC per culture of 250,000 cells). Antibodies used for staining were CD3-PE (clone SK7, 
Becton Dickinson (BD) Biosciences, Erembodegem, Belgium) and CD4-APC (clone MT4 66, Miltenyi Biotech) 
or CD123-FITC (clone AC145, Miltenyi Biotech), CD303-APC (clone AC144, Miltenyi Biotech) and CD304-
PE. Except when used for lentiviral transduction (see below), primary CD4+ T cells cells were cultured for 3 
days after isolation at 37 °C in a 5 % (v/v) CO2 humidified atmosphere in RPMIc: Gibco® RPMI medium 1640 
(Life Technologies, Merelbeke, Belgium) supplemented with 2 mM L-glutamin (Life Technologies), 10 % (v/v) 
heat-inactivated fetal calf serum (Hyclone, Thermo Fisher Scientific, Waltham, MA), 100 U/mL penicillin and 
100 µg/mL streptomycin (Life Technologies). RPMIc was supplemented with 20 ng/mL interleukin-2 (IL-2; 
specific activity 10 U/ng, Peprotech, London, United Kingdom), and with 1 µg/mL phytohemagglutinin (PHA) 
mitogen (Thermo Fisher Scientific). Subsequently, cells were infected with HIV. 
293T cells (DZSM, Braunschweig, Germany), MT4 cells (kind gift from Dr. Katrien Fransen, Institute of 
Tropical Medicine, Antwerp, Belgium) used for co-culture with primary CD4+ T cells, TZM-bl cells expressing 
human STING (kind gift from Dr. Oliver Fackler, University Hospital Heidelberg, Heidelberg, Germany 
(Trotard et al. 2016)) and Jurkat CD4 CCR5 cells (Programme EVA Centre for AIDS Reagents, NIBSC, UK) 
were cultured at 37°C in a 7 % (v/v) CO2 humidified atmosphere, in IMDMc (293T, MT4) or DMEMc (TZM-
bl): IMDM or DMEM (Life Technologies) supplemented with 10 % (v/v) fetal bovine serum, 2 mM L-glutamin, 
100 U/mL penicillin and 100 µg/mL streptomycin. MT4C5 cells (a derivate MT4 cells expressing CCR5) were 
used for co-culture with MDDCs and were cultured as described in Lepelley et al. 2011. HL-116 cells (kindly 
provided by Dr. Uze, University of Montpellier II, France (Uze et al., 1994)) were cultured at 37 °C in a 7 % 
(v/v) CO2 humidified atmosphere in DMEM (Life Technologies) supplemented with 10 % fetal bovine serum 
and 2 mM L-glutamin (DMEMc). 
Monocytes were isolated by positive CD14 immunomagnetic selection (Miltenyi Biotec) from PBMCs of 
healthy donors. MDDCs were generated by culturing monocytes for 5 days in the presence of IL-4 (50 ng/mL) 
and GM-CSF (10 ng/mL) as described in (Puigdomenech et al., 2013). 
 
Viral constructs  
Characteristics and sources of the plasmids used for production of HIV-1 in this study are described in the table 
below. 
 
HIV-1 encoding vectors used in this study. 
Parental 
vector 
Variant Virus referred to as: Source Reference 
NLENG1-
IRES 
WT HIV NL4-3-GFP-I 
Dr. D.N. Levy, 
New York 
University college 
of Dentistry, New 
York, NY 
Kutsch et al., 2002; 
Levy et al., 2004 
NL4-3-IRES-
HSA 
WT HIV NL4-3-HSA-I 
Dr. M.J. Tremblay; 
Faculté de 
Médecine, 
Université Laval, 
Québec, Canada 
Imbeault et al., 2009 
Tat-defective 
HIV NL4-3-HSA-I 
TatSTOP 
Constructed in 
house 
See Materials and 
methods 
Vpr-defective 
HIV NL4-3-HSA-I 
dVpr 
Constructed in 
house 
See Materials and 
methods 
pNL4-3 WT HIV NL4-3 NIH AIDS Adachi et al., 1986 
Research and 
Reference Reagent 
Program 
Integrase-mutated HIV NL4-3 D116N 
Dr. Z. Debyser, 
Laboratory for 
Molecular Virology 
and Gene Therapy, 
KU Leuven, 
Belgium 
Mutation introduced 
in HIV NL4-3 
(according to 
Engelman et al., 
1995) 
Vpr-deleted HIV NL4-3 dVpr 
Dr. Margottin-
Goguet, Institute 
Cochin, Paris, 
France 
Le Rouzic et al., 2008 
Vpr Q65R mutant HIV NL4-3 Q65R 
Constructed in 
house 
See Materials and 
methods 
Vpr R77Q mutant HIV NL4-3 R77Q 
Constructed in 
house 
See Materials and 
methods 
pLaiΔEnv-
GFP3 
WT HIV LAI dEnv dNef 
Dr. N. Manel, 
Institut Curie, Paris, 
France 
Manel et al., 2010 
Capsid G89V 
mutant 
HIV LAI dEnv dNef 
G89V 
Manel et al., 2010 
Capsid T54A/N57A 
mutant 
HIV LAI dEnv dNef 
T54A/N57A 
Manel et al., 2010 
Capsid 
Q63A/Q67A 
mutant 
HIV LAI dEnv dNef 
Q63A/Q67A 
Manel et al., 2010 
pBR-NL43-I-
EGFP 
WT HIV NL4-3-I-EGFP 
Constructed in 
house 
Schindler et al., 2003 
Vpu-deleted 
HIV NL4-3-I-EGFP 
dVpu 
Rucker et al., 2004;  
nef-IRES-eGFP 
introduced as 
described in Sauter et 
al., 2009 
Vpr-deleted 
HIV NL4-3-I-EGFP 
dVpr 
Rucker et al., 2004;  
nef-IRES-eGFP 
introduced as 
described in Sauter et 
al., 2009 
Vpu-deleted and 
Vpr-deleted 
HIV NL4-3-I-EGFP 
dVpu dVpr 
Rucker et al., 2004;  
nef-IRES-eGFP 
introduced as 
described in Sauter et 
al., 2009 
pNL4-3 UIE 
WT 
HIV NL4-3-Vpu-
IRES-Env NL4-3 WT 
(M) 
Constructed in 
house 
Sauter et al., 2009 
Vpu NL4-3 S52 
mutant 
HIV NL4-3-Vpu-
IRES-Env NL4-3 S52 
Sauter et al., 2009 
Vpu NL4-3 STOP 
HIV NL4-3-Vpu-
IRES-Env NL4-3 
STOP 
Sauter et al., 2009 
Vpu NL4-3 deleted 
HIV NL4-3-Vpu-
IRES-Env NL4-3 
deleted 
Sauter et al., 2009 
Vpu HIV-1 M 
JRCSF 
HIV NL4-3-Vpu-
IRES-Env JRCSF (M) 
Sauter et al., 2009 
Vpu HIV-1 M Yu2 
(adapted) 
HIV NL4-3-Vpu-
IRES-Env Yu2 (M) 
Sauter et al., 2009 
Vpu HIV-1 O 
13127 
HIV NL4-3-Vpu-
IRES-Env 13127 (O) 
Sauter et al., 2009 
Vpu SIV Cpz Pts HIV NL4-3-Vpu- Sauter et al., 2009 
Tan1 IRES-Env Cpz Pts 
Tan1 
Vpu SIV Cpz Ptt 
MP7 
HIV NL4-3-Vpu-
IRES-Env Cpz Ptt MP7 
Sauter et al., 2009 
Table shows different HIV-1 constructs used in this study, indicating the parental wild-type (WT) vector and 
variants used; the name by which this virus is referred to in the study, the source of the vector and the reference 
describing construction of the vector if published. 
 
The tat-defective and vpr-defective NL4-3-IRES-HSA vectors were created by site directed mutagenesis on a 
part of the parental backbone, followed by substitution of the mutated fragment (with verified sequence) in the 
parental backbone. For mutation of tat, a TGA stop codon was introduced after the ATG start codon of the first 
exon of tat. For mutation of vpr, the CTAGAGCTTTTAGAGAA sequence at the end of the vif-vpr overlapping 
reading frame, was replaced by a CTAGTGATTGAATAGGAA sequence, thereby introducing a stop codon in 
vpr in each of the reading frames after the end of vif.  
The HIV NL4-3 constructs encoding viruses with Q65R and R77Q mutations in Vpr, were generated by 
introducing point mutations in HIV NL4-3 WT with the QuikChange XL Site-Directed Mutagenesis kit 
(Stratagene, Agilent Technologies, La Jolla, CA), using the primers described in table below. 
 
Primers used for mutation of vpr in HIV NL4-3 viruses. 
Mutation Forward primer Reverse Primer 
Q65R 
5’-
agtggaagccataataagaattctgagacaactgctgtttattcatt
tcaga-3’ 
5’-
tctgaaatgaataaacagcagttgtctcagaattcttattatggcttc
cact-3’ 
R77Q 
5’-
gaattatgcctattctgctatgttgacacccaattctgaaatgaata-
3’ 
5’-
tattcatttcagaattgggtgtcaacatagcagaataggcataattc
-3’ 
 
The LZRS-Vpr-IRES-NGFR retroviral vector used for complementation of HIV viruses with a wild-type Vpr 
protein during production, was constructed by PCR amplification of the vpr gene from the NL4-3-IRES-HSA 
vector and introduction into LZRS-IRES-NGFR (Stove et al., 2005), expressing Nerve Growth Factor Receptor 
(NGFR) as a marker gene. 
 
Production of HIV 
HIV production was done by transfection of 293T cells with Calcium Phosphate Transfection Kit (Life 
Technologies) or JetPei® (Polyplus, Sélestat, France), according to manufacturer’s instructions using 5 µg of 
HIV plasmid per 750,000 cells. For VSV-G pseudotyped viruses, cells were transfected with 1 µg pMD.G 
plasmid (Stove et al., 2005) and 4 µg of HIV plasmid. Medium was refreshed 24 h after transfection. Viral 
supernatant was harvested after 48 h and centrifuged at 900 g for 10 min, to clarify the supernatant from 
remaining cells. Viral titer was determined by measuring reverse transcriptase activity in the supernatant with the 
SG-PERT assay (as described in Vermeire et al., 2012). Production of VSV-G pseudotyped HIV NL4-3 WT and 
dVpr viruses used in context of MDDC experiments was performed as previously described (Puigdomenech et 
al., 2013). 
For production of wild-type and gag-mutated VSV-G pseudotyped HIV-1 LAI dEnv dNef viruses complemented 
with a wild-type capsid protein, 293T cells were transfected with 2.7 µg HIV plasmid, 1.7 µg pCMV-ΔR8.91 
(kindly provided by Dr. N. Manel (Manel et al., 2010) and 0.7 µg pMD.G plasmid using JetPei®. Viral 
supernatant was harvested as indicated above. 
For complementation of wild-type and vpr-defective HIV NL4-3-HSA-I virions with a wild-type Vpr protein, 
293T cells were transfected with 1.7 µg HIV plasmid and 3.3 µg LZRS-Vpr-IRES-NGFR (Vpr complemented) 
or LZRS-IRES-NGFR (control vector) using JetPei®. Viral supernatant was harvested as indicated above and 
transfection efficiency was determined at the time of harvesting by surface staining with anti-CD24-APC and 
anti-NGFR-PE (clone ME20.4, Chromaprobe, Maryland Heights, MO). Percentage of CD24+NGFR+ cells was 
determined by flow cytometry (FACSCalibur, BD Biosciences) and always > 40 %. Efficacy of Vpr 
complementation using this protocol was previously validated by measurement of Vpr protein levels by Western 
Blot. In some experiments, supernatants of complemented viruses with low titer were concentrated using PEG-it 
precipitation of viral particles following manufacturer’s instructions (PEG-itTM Viral Precipitation Solution, 
System Biosciences, Mountain View, CA) and subsequent resuspension in IMDMc in 1/5 of the original volume.  
HIV-1 group M A8 isolate (92UG029) (Bachmann et al., 1994) was obtained from the NIH AIDS Research and 
Reference Reagent Program. The HIV-1 group M D2 (VI203) (Louwagie et al., 1993) and HIV-2 CI85 (Arien et 
al., 2005) strains were previously isolated from patients attending the AIDS clinic at the Institute of Tropical 
Medicine in Antwerp, Belgium, with the approval of the ethical committee after written informed consent. Virus 
stocks were initially obtained after propagation in short-term cultures of PBMCs as described before (Arien et 
al., 2005) and subsequently expanded by infection and culture of Jurkat CD4 CCR5 cells. To this end, cells were 
plated at 5 x 105 cells per well of a 12-well flat-bottom plate (BD Biosciences) in 1 mL IMDMc and 1 mL of 
PBMC-derived viral supernatant was added to the cells (viral titer ranging from 350-1150 mU RT/ mL, 
equivalent to 35-210 ng p24/mL). Supernatant of the Jurkat CD4 CCR5 cells was collected at peak of infection 
and centrifuged at 900 g for 10 min, to clarify the supernatant from remaining cells.  
 
Infection with HIV  
For HIV infection of primary CD4+ T cells, 250,000 cells were seeded per well in a 96-well flat-bottom plate 
(BD Biosciences) in RPMIc supplemented with 20 ng/mL IL-2 (final concentration). Depending on the 
experiment 6-3000 mU RT (equivalent to 1–550 ng p24) of HIV virus was added per well in a final volume of 
200 µL, with low concentrations (1-40 ng p24) used for long-term experiments (read-out until day 5-7 after 
infection) and high concentrations (60-550 ng p24) used for short-term experiments (last read-out at day 1-3 
after infection). Cells were subsequently spinoculated at 950 g for 90 min at 32 °C. Medium was refreshed with 
RPMIc (+ IL-2) immediately after spinoculation and for half of the volume every 2 days during subsequent 
culture. At the indicated time points after infection, cells were harvested to determine HIV infection levels and 
remaining cells were lysed in 700 µL QIAZOL (miRNeasy mini kit, QIAGEN, Venlo, The Netherlands) 
according to manufacturer’s instruction. Supernatant of the cells was collected after spinoculation of the cells at 
350 g for 10 min at 4 °C. Lysates and supernatants were stored at -80 °C until further use.  
For HIV-1 infection in the presence of IFN-α and/or IFN-β neutralizing antibodies, primary CD4+ T cells were 
resuspended immediately after spinoculation in medium containing 1/100,000x diluted goat anti-human IFN-β 
serum (925, kindly provided by Dr. Van Damme, Rega Institute, KUL, Belgium (Van Damme et al., 1987)) 
and/or 6,000 neutralizing units (NU)/ mL rabbit polyclonal anti-human IFN-α antibody (PBL Assay Science, 
Piscataway, NJ). Every 2 days, new medium with antibodies was added to the cells. Neutralizing capacity of the 
antibodies was verified by incubating them with recombinant IFNα1b or IFNβ1a (Immunotools, Friesoythe, 
Germany) and evaluating remaining IFN-I activity with the HL-116 assay. 
For HIV-1 infection in the presence of antiretrovirals, primary CD4+ T cells were plated in medium with 5 µM 
nevirapine, 0.5 µM raltegravir or 1 µM ritonavir (AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH, Germantown, MD) 1 h before infection and antiretrovirals were maintained at these 
concentrations during infection. Antiretrovirals were titrated on primary CD4+ T cells prior to use to verify 
inhibition of HIV NL4-3-GFP-I replication.  
For HIV-1 infection in the presence of a TAK1 inhibitor, primary CD4+ T cells were plated in medium with 50 
nM (5Z)-7-oxozeaenol (Tocris Bioscience, Bristol, UK) immediately before infection and inhibitor was 
maintained at this concentration during infection.  
MT4 cells were infected with HIV NL4-3-GFP-I viruses by plating 1.5 x 106 cells per well of a 6-well flat-
bottom plate (BD Biosciences) and addition of 165-350 mU RT (equivalent to 30-60 ng p24) of virus in a total 
volume of 6 mL IMDMc. Cells were subsequently spinoculated at 950 g for 90 min at 32 °C. 48 h-72 h after 
infection, cells were collected and used for co-culture with primary CD4+ T cells. 
STING expressing TZM-bl cells were infected with HIV NL4-3-HSA-I viruses by plating 60,000 cells per well 
of a 12-well flat bottom plate (BD Biosciences) one day beforof and addition of 1100-4400 mU RT (equivalent 
to 200-800 ng p24) of virus in a total volume of 4.2 mL DMEMc. Cells were subsequently spinoculated at 950 g 
for 90 min at 32 °C. 48h after infection, cells were harvested to determine HIV infection levels and remaining 
cells were lysed in 700 µL QIAZOL (miRNeasy mini kit, QIAGEN, Venlo, The Netherlands) according to 
manufacturer’s instruction. 
For infection of MDDCs, 8 x 104 MDDCs were seeded in flat-bottomed 96-well plates. MT4C5 cells were 
infected with VSV-G pseudotyped HIV NL4-3 WT or dVpr, 24-48 h before the start of the co-culture. Donor T 
cells were stained with Far Red DDAO-SE (Life Technologies). MT4C5 cells were then co-cultured with 
MDDC at a 1:2 ratio (T:MDDC). Non-infected MT4C5 cells were used as negative controls. Co-cultures were 
performed for 72 h. VLPs carrying Vpx were produced as previously described (Puigdomenech et al., 2013) and 
added to MDDCs 2 h before HIV-1 infection and maintained during the experiment. 
 
Origin and production of lentiviral vectors 
Lentiviral TRC1 pLKO.1-puro vectors (Sigma-Aldrich, St. Louis, MO) encoding shRNA are listed in the table 
below and were mostly obtained from the BCCM/LMBP Plasmid collection, Department of Biomedical 
Molecular Biology, Ghent University, Belgium (http://bccm.belspo.be/about/lmbp.php). For knock-down of 
IRF3, a pLKO.1-puro vector targeting IRF3 was kindly provided by Dr. N. Manel (Institut Curie, Paris, France) 
(Manel et al. 2010). As a control, a pLKO.1-puro vector encoding a non-targeting scrambled shRNA (SHC-002) 
was purchased from Sigma-Aldrich. Lentiviruses were produced in 293T cells by transfection with the pLKO.1 
vectors and the MISSION® Lentiviral Packaging Mix using FuGENE® HD Transfection Reagent (Promega, 
Leiden, The Netherlands) as described before (Landi et al., 2014). Medium was refreshed 24 h after transfection. 
Viral supernatant was harvested after 48 h and centrifuged at 900 g for 10 min, to clarify the supernatant from 
remaining cells.  
 
List of pLKO.1-puro shRNA-encoding lentiviral vectors used for knock-down of host proteins.  
Origin 
lentiviral 
vector 
Target 
gene 
(official 
symbol) 
Refseq TRC number / 
reference 
Target sequence Targete
d gene 
region 
BCCM/L
MBPa 
MB21D1 NM_138441.2 
TRCN0000148
694 
CTGCCTTCTTTCACGTATGT
A 
CDS 
BCCM/L
MBPa 
MB21D1 
(#2) 
NM_138441.2 
TRCN0000149
984 
CAACTACGACTAAAGCCAT
TT 
CDS 
BCCM/L
MBPa 
MB21D1 
(#3) 
NM_138441.2 
TRCN0000146
282 
CTTTGATAACTGCGTGACA
TA 
CDS 
BCCM/L
MBPa 
TMEM173 
NM_001301738.1, 
NM_198282.3 
TRCN0000161
052 
GCTGGCATGGTCATATTAC
AT 
CDS 
BCCM/L
MBPa 
TBK1 NM_013254.3 
TRCN0000003
182 
GCAGAACGTAGATTAGCTT
AT 
CDS 
BCCM/L
MBPa 
PQBP1 
(#1) 
NM_001032381.1, 
NM_001032382.1, 
NM_001032383.1, 
NM_001032384.1, 
NM_001167989.1, 
NM_001167990.1,  
NM_001167992.1, 
NM_005710.2, 
NM_144495.2, 
XM_005272571.3, 
XM_005272572.3, 
XM_011543884.1 
TRCN0000019
941 
CCCTTACTACTGGAATGCA
GA 
CDS 
BCCM/L
MBPa 
PQBP1 (#2 
) 
NM_001032381.1, 
NM_001032382.1, 
NM_001032383.1, 
NM_001032384.1, 
 NM_001167989.1, 
NM_001167990.1,  
NM_001167992.1, 
NM_005710.2, 
NM_144495.2, 
XM_005272571.3, 
XM_005272572.3, 
XM_011543884.1 
TRCN0000019
942 
GAGATCATTGCCGAGGACT
AT 
CDS 
BCCM/L
MBPa 
VPRBP 
(DCAF1) 
NM_001171904.1,  
NM_014703.2 
TRCN0000129
579 
CCTCCCATTCTTCTGCCTTT
A 
CDS 
Dr. N. 
Manel, 
Institut 
Curie, 
Paris, 
France 
IRF3 
NM_001197125.1, 
NM_001197126.1, 
NM_001197123.1, 
NM_001197122.1, 
NM_001571.5 
Manel et al. 
2010 
CTGCCTGGATGGCCAGTCA
CAC 
CDS 
Sigma-
Aldrich 
Non-
targeting 
scrambled 
shRNA 
control 
(SHC-002) 
Not applicable Not applicable Not applicable 
Not 
applicab
le 
Table shows official gene symbol of the shRNA targeted gene according to the HUGO Gene Nomenclature 
Committee database (www.genenames.org); Refseq code of the targeted transcripts (Reference sequence 
database of National Center for Biotechnology Information (www.ncbi.nlm.nih.gov)); TRC number of the clone 
from the Sigma Mission® TRC1 lentiviral library, sequence in the gene transcript targeted by the shRNA and 
corresponding region in the transcripts targeted (CDS: coding sequence). 
aSigma Mission® TRC1 vector obtained through the BCCM/LMBP Plasmid collection, Department of 
Biomedical Molecular Biology, Ghent University, Belgium (http://bccm.belspo.be/about/lmbp.php) 
 
Knock-down of host genes by lentiviral vector transduction and subsequent infection with cell-free HIV-1 or co-
culture with HIV-1 infected cells 
pDC depleted primary CD4+ T cells were transduced immediately after isolation from peripheral blood with 
pLKO.1 lentiviral vectors. Cells were plated at 300,000 cells in 55 µL RPMIc per well of a 96-well flat bottom 
plate and 45 µL of lentiviral vector supernatant was added to each well in the presence of 20 ng/mL IL-2, 1 
µg/mL PHA and 8 µg/mL polybrene. Cells were then spinoculated for 30 min, 950 g at 32 °C. After 24 h, fresh 
RPMIc containing IL-2 and PHA was added to the cells. 48 h after transduction puromycin (1.2 µg/mL final 
concentration, Sigma-Aldrich) was added to the cells. After 72 h, PHA/IL-2 stimulation was ended by removing 
all medium and adding fresh RPMIc containing IL-2 and puromycin. 5 days after transduction cells were 
counted using MACSquant® Analyzer or using Flow-count Fluorospheres (Beckman Coulter, Suarlée, Belgium) 
and FACSCalibur flow cytometer, according to manufacturer’s instructions. For infection with cell-free HIV-1, 
cells were plated at 2 x 105 – 2.5 x 105 cells per well of a 96-well flat bottom plate and infected by spinoculation 
as described above. For infection through co-culture with HIV-1 infected MT4 cells,  
cells were plated at 1.2 x 105–1.5 x 105 cells per well and an equal amount of HIV-infected or non-infected MT4 
cells were added in a total volume of 200 µL fresh RPMIc (+ IL-2). Remaining primary CD4+ T cells were lysed 
in QIAZOL prior to infection or co-culture and used for target gene expression analysis. 24 h after the start of the 
co-culture or 48 h after infection with cell-free HIV-1, cells were lysed in QIAZOL and used for IFN-β and/or 
IFIT1 expression analysis. IFN-β mRNA induction was not observed after co-culture of HIV-infected MT4 cells 
and primary CD4+ T cells when infection was blocked by HIV-1 reverse transcriptase inhibitor nevirapine (data 
not shown).  
For stimulation of cells with cGAMP, cells were plated at 2.5 x105 cells per well of a 96-well flat bottom plate 
and incubated with 10 μg/mL of synthetic 2’,3’ cGAMP (Invivogen, Toulouse, France) after pre-incubation with 
Lipofectamine® 2000 (Life Technologies) at a 4:1 ratio (μg cGAMP : μL Lipofectamine® 2000). 24 h after 
treatment, cells were lysed in QIAZOL and used for IFN-β and/or IFIT1 expression analysis. 
Western Blot 
For analysis of cGAS expression levels, primary CD4+ T cells transduced with shRNA-encoding vectors and 
selected with puromycin were lysed in Laemli sample buffer (0.125 M 
Tris, pH 6.8, 25 % glycerol, 2.3 % SDS). Lysates were sheared and protein concentrations were determined by 
RC DC Protein Assay (Bio-Rad). Equal amounts of protein were separated on a BOLT 4–12 % Bis-Tris Plus gel 
(Thermo Fisher Scientific), blotted onto PVDF membranes (Invitrogen) in reducing conditions and probed with 
an antibody against cGAS (rabbit anti-human MB21D1; diluted 1:500, Sigma-Aldrich). Subsequently, blots were 
probed with HRP-conjugated donkey anti-rabbit antibody (1:4000, ECL Rabbit IgG, GE Healthcare Life 
Sciences, Diegem, Belgium). The signal was generated using a Super Signal West Femto Maximum Sensitivity 
Substrate (Thermo Fisher Scientific), detected by chemoluminescence with the ImageQuant LAS 4000 (GE 
Healthcare Life Sciences). For staining of ß-actin, blots were stripped with Restore Plus Western Blot stripping 
buffer (Thermo Fisher Scientific) according to manufacturer’s instructions and probed with an anti-ß-actin 
antibody (mouse monoclonal ß-actin, BA3R, diluted 1:1000, Thermo Fisher Scientific). Secondary staining was 
performed with a HRP-conjugated sheep anti-mouse antibody (1:2000, sheep anti-mouse whole ECL antibody, 
GE Healthcare) and signal was generated and detected as described above. 
 
Quantitative real-time PCR (qPCR) 
RNA was isolated from QIAZOL lysates using the miRNeasy mini kit, either manually or with QIAcube 
(Qiagen), according to manufacturer’s instructions. RNA (max. 1 µg) was subsequently treated with 
amplification-grade DNAse I (Life Technologies) and used for synthesis of cDNA with Superscript® III reverse 
transcriptase and random primers (Life Technologies), all according to manufacturer’s instructions. Depending 
on the gene to measure, cDNA was subsequently 3x (for target genes)-15x (for reference genes) diluted by 
addition of Nuclease-Free Water (NFW) (Ambion, Life Technologies) and 5 µL of diluted cDNA was used as 
input for qPCR. For qPCR measurement of YWHAZ, UBC, IFIT1, IFN-α and IRF3, forward (FWD) and reverse 
(REV) primers were used at a final concentration of 300 nM in combination with 2x concentrated LightCycler® 
480 SYBR Green I Master mix (Roche Diagnostics, Vilvoorde, Belgium) in a final reaction of 15 µL. For 
measurement of IFN-β (IFNB1), FWD and REV primers were used at a final concentration of 500 nM and a 
double-quencher probe (56-FAM/ZEN/3′ Iowa Black FQ) was used at a final concentration of 250 nM in 
combination with 2x concentrated LightCycler® 480 Probes Master mix (Roche Diagnostics) in a final reaction 
of 15 µL. Primers and probe were manufactured by IDT (Leuven, Belgium). For measurement of MB21D1 
(cGAS), TMEM173 (STING), TBK1and PQBP1 20x concentrated commercial Prime PCR Sybr® Green assays 
(Bio-Rad Laboratories, Temse, Belgium) were used in combination with 2x concentrated LightCycler® 480 
SYBR Green I Master mix or 2x concentrated SsoAdvancedTM Universeal SybrGreen® Supermix (Bio-Rad 
Laboratories) in a final reaction of 15 µL. Primer/probe sequences or assay IDs are listed in the table below. 
qPCR reactions were performed in 384-well plates (LightCycler® 480 Multiwell Plates 384, white, Roche 
Diagnostics) on the on the LightCycler® 480 II instrument (Roche Diagnostics) using following program: 10 
min at 95 °C; 45 cycles of amplification: 10 s at 95 °C, 1 min at 60 °C. 
For each sample, qPCR reactions were performed in duplo. A non-template control (NFW instead of cDNA) and 
a serial 10-fold dilution of cDNA derived from poly I:C stimulated PBMCs (standard curve) was included for 
measurement of each gene on each plate. Cycles of quantification (Cq) values were generated by the 
LightCycler® 480 software 1.5.0 according to the second-derivative maximum method. Amplification efficiency 
of each qPCR assay was tested during primer/assay validation and varied from 85-105 %. Melting curve analysis 
was performed for the not previously validated SYBR Green assays (IFIT1, IFN-α and IRF3) and showed a 
single peak. Calibrated normalized relative quantities (CNRQs) were calculated for each target gene in each 
sample based on obtained Cq values, with the qBasePlus Software (Biogazelle, Zwijnaarde, Belgium), using 
YWHAZ and UBC as reference genes and using target- and run- specific amplification efficiencies. GeNorm 
analysis (implemented in qBase Plus) was used to select YWHAZ and UBC as stable reference genes in prior 
experiments.  
 
Properties of the qPCR assays used. 
Official 
gene 
symbol 
Detected 
Refseq 
transcripts 
Primer/probe 
sequence source 
Primer
/ 
probe 
identit
y 
Primer/probe sequence  Ampl
i-con 
lengt
h 
YWHA
Z 
NM_001135702
.1, 
NM_001135701
.1, 
NM_001135700
.1, 
NM_001135699
.1, 
NM_145690.2, 
NM_003406.3 
RTprimerDB ID: 9 
(Pattyn et al., 2003) 
FWD 
5’-
ACTTTTGGTACATTGTGGCTTC
AA-3’ 
94 
REV 
5’-
CCGCCAGGACAAACCAGTAT-3’ 
UBC NM_021009.6 
RtprimerDB ID: 8 
(Pattyn et al., 2003) 
FWD 5’-ATTTGGGTCGCGGTTCTTG-3’ 
133 
REV 
5’-
TGCCTTGACATTCTCGATGGT-3’ 
IFIT1 NM_001548.4 
Designed with 
Primer-BLAST (Ye 
et al., 2012) 
FWD 
5’-
GATCTCAGAGGAGCCTGGCTAA
-3’ 
84 
REV 
5’-
TGATCATCACCATTTGTACTCA
TGG-3’ 
IFNA 
cluster 
(IFNA10
NM_002171.2, 
NM_021268.2, 
NM_021068.2, 
RTprimerDB ID: 
3541 (Pattyn et al., 
2003) 
FWD 
5’-
GTGAGGAAATACTTCCAAAGA
ATCAC-3’ 
93 
, 
IFNA17, 
IFNA4, 
IFNA2, 
IFNA8, 
IFNA7, 
IFNA14, 
IFNA21, 
IFNA16, 
IFNA6, 
IFNA1, 
IFNA13, 
IFNA5) 
NM_000605.3, 
NM_002170.3, 
NM_021057.2, 
NM_002172.2, 
NM_002175.2, 
NM_002173.2, 
NM_021002.2, 
NM_024013.2, 
NM_006900.3, 
NM_002169.2 
REV 
5’-
TCTCATGATTTCTGCTCTGACA
A-3’ 
IFNB1 NM_002176.2 
Designed with 
PrimerQuest Assay 
design IDT 
FWD 
5’-
GCTTCTCCACTACAGCTCTTTC-
3’ 
115 REV 
‘5-
CAGTATTCAAGCCTCCCATTCA-
3’ 
PROB
E 
56-
FAMTTCAGTGTC/ZEN/AGAAGC
TCCTGTGGCAA/3IABkFQ 
IRF3 
NM_001197125
.1, 
NM_001197124
.1, 
NM_001197123
.1, 
NM_001197122
.1, 
NM_001571.5 
Viemann et al., 2011 
FWD 
5’-
AGGCCACTGGTGCATATGTTC-
3’ 
108 
REV 
5’-
CCTCTGCTAAACGCAACCCTT-
3’ 
MB21D
1 
n.a. 
qHsaCID0009796 
Bio-rad Laboratories 
/ n.a. 110 
TMEM1
73 
n.a. 
qHsaCID0010565 
Bio-rad Laboratories 
/ n.a. 93 
TBK1 n.a. 
qHsaCID0018552 
Bio-rad Laboratories 
/ n.a. 141 
PQBP1 n.a. 
qHsaCID0037960 
Bio-rad Laboratories 
/ n.a. 80 
Table shows properties of primers used for qPCR: official gene symbol according to the HUGO Gene 
Nomenclature Committee database (www.genenames.org); detected Refseq transcripts are those obtained by 
Primer-BLAST (Ye et al., 2012) using the indicated primer sequences with default parameters; FWD: forward 
primerr, REV: reverse primer, n.a. not available 
Measurement of secreted type 1 IFN bioactivity 
HL-116 cells were plated 16 h prior to the assay at 40,000 cells per well of a 96-well-flat bottom plate in 200 µL 
DMEMc. Medium was removed and 100 µL culture supernatant or recombinant IFNα, together with 100 µL 
DMEMc was added. Cells were incubated for 7-8 h, washed with PBS and lysed (Cell Culture Lysis 5X 
Reagent, Promega). Lysates were either processed immediately or stored at -80°C until further use. For 
measurement of luciferase activity, 20 µL cell lysate was transferred to 96-well white solid plates 
(Costar/Corning, Amsterdam, The Netherlands) and luciferase assay was conducted using 50 µL Luciferase 
reagent (Luciferase Assay System, Promega) in a TriStar LB 941 automated plate reader (Berthold 
Technologies, Bad Wildbad, Germany). IFN-I levels are expressed in IU/mL as equivalent of IFNα1b 
(Immunotools, Friesoythe, Germany) bioactivity for primary CD4+ T cells and as equivalent of IFNα2a (PBL 
Assay Science) bioactivity for MDDC experiments, both determined by inclusion of a dilution series of the 
recombinant IFNα in each experiment.  
 
Measurement of MxA and HIV infection levels. 
Intracellular staining for p24 or MxA in primary CD4+ T cells was performed with the Fix and Perm Cell kit 
(AN DER GRUB Bio Research, Susteren, The Netherlands) according to manufacturer’s instructions using 
following antibodies: HIV-1 core antigen PE (phycoerythrin)-conjugated mAb (Clone KC57, Beckman Coulter, 
Suarlée, Belgium) for p24 or anti-MxA (anti-MX1) (rabbit polyclonal, Abcam, Cambridge, UK)/ rabbit control 
serum (Cell Signaling Technology, Leiden, The Netherlands) as primary antibody and Alexa Fluor® 660 goat 
anti-rabbit IgG (Life Technologies) as secondary antibody for MxA. For HIV NL4-3-HSA-I infected cells, 
surface staining was performed with an anti-CD24-APC (allophycocyanin) antibody (HSA; mouse clone M1/69, 
BioLegend, San Diego, CA). Cells were analyzed by flow cytometry (FACSCalibur using CellQuest Pro 
software (BD Biosciences) or FlowJo 887 (Tree Star, Ashland, OR) or Flowing Software (Turku Centre for 
Biotechnology, University of Turku) for analysis; MACSQuant flow cytometer (Miltenyi Biotec) using 
MACSQuantifyTM version 2.5 for analysis). Living cells were gated as propidium-iodide staining negative cells 
after forward scatter (FSC) and side scatter (SSC) gating. For HIV-2 CI85 infected cells, surface staining was 
performed with an anti-CD4-APC antibody (clone M-T466, Miltenyi Biotec). Percentage of HIV-1 infected cells 
was determined as percentage of HSA, GFP or p24 expressing cells and for HIV-2 CI85 as percentage of CD4low 
cells. For evaluation of HIV-1 infection levels in co-cultures, cells were stained with anti-CD3-APC antibody 
(clone SK7, BD Biosciences) and percentage of HIV-1 infected primary CD4+ T cells was determined by flow 
cytometry as percentage of GFP+ cells among CD3high cells.  
To quantify virion release, supernatant from infected cultures was harvested and centrifuged at 350 g for 10 min, 
to clarify the supernatant from remaining cells. Reverse transcriptase activity in the supernatant was 
subsequently determined with the SG-PERT assay (as described in Vermeire et al., 2012). 
To evaluate HIV-1 infection levels in MDDCs, cells were intracellularly stained with anti-HIV-Gag (KC57-PE, 
Beckman-Coulter) and Gag-PE and Far Red DDAO-SE levels were analyzed by flow cytometry.  
 
Statistical analysis and software  
Figures were created with Microsoft PowerPoint and GraphPad Prism 5.0 software. Statistical tests were 
performed with GraphPad Prism 5.0 as indicated in the figure legends.  
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